tim boreham, page-2

FWIW this is what he said.

In the biotech sphere, Cellestis (CST, $3.46) has defied the sector's dodgy reputation with a 391 per cent profit boost to $8.23m, on an 80 per cent revenue surge to $35m.

Cellestis sells the tuberculosis testing kit Quantiferon. Its key markets are not darkest Africa but the US, Europe and Japan, which means TB isn't just a vestige of BBC period dramas.

With a $332m market cap (including $19m cash) Cellestis isn't exactly a penny-dreadful speccie play. Hold.